This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Galli, S. M. Articles by Phillips, M. I. Search for Related Content PubMed PubMed Citation Articles by Galli, S. M. Articles by Phillips, M. I. Pubmed/NCBI databases Compound via MeSH Substance via MeSH Hazardous Substances DB SODIUM Related Collections Primary prevention ACE/Angiotension receptors Animal models of human disease Other hypertension Genomics Hypertension - basic studies Gene therapy

(Hypertension. 2001;38:674.)
© 2001 American Heart Association, Inc.

Renin-Angiotensin System

Angiotensin II AT_1A Receptor Antisense Lowers Blood Pressure in Acute 2-Kidney, 1-Clip Hypertension

Sara M. Galli; M. Ian Phillips

From the Department of Physiology, College of Medicine, University of Florida, Gainesville.

Correspondence to Sara M. Galli, Department of Physiology, University of Florida, Box 100274, College of Medicine, Gainesville, FL 32610. E-mail SMGalli{at}phys.med.ufl.edu

Abstract

Abstract—— To test the effectiveness of antisense oligonucleotides targeted to the angiotensin type 1A (AT_1A) receptor mRNA on blood pressure reduction, the 2-kidney, 1-clip (2K1C) Goldblatt model of hypertension was studied in the acute phase of hypertension, when the peripheral renin-angiotensin system is overactive. A single injection of AT_1A receptor antisense oligodeoxynucleotides significantly reduced systolic blood pressure for a period of 8 days in 2K1C rats after clipping, from 157.5±5 mm Hg on day 7 to 141.3±3.0 mm Hg on day 15 after clipping (P<0.01). The AT_1A receptor antisense oligonucleotide labeled with fluorescein shows that the antisense oligonucleotide at 24 hours was taken up into aorta, mesenteric artery, liver, kidney glomeruli, and medulla, remaining up to 6 days. The AT_1A receptor number in fmol/g tissue was significantly decreased after AT_1A receptor antisense oligonucleotide treatment in the dorsal aorta, mesenteric artery, renal cortex, and renal medulla (P<0.05) compared with that of the AT_1A receptor-scrambled antisense oligonucleotide control-treated group. The data clearly demonstrate a prolonged antihypertensive effect of AT_1A receptor antisense oligonucleotide in the 2K1C renovascular model of hypertension when it is administered intravenously in a single low dose (0.33 mg/kg^-1). It also shows that the AT_1A receptor antisense oligonucleotide is actively taken up by AT_1A target tissues and that there is a significant decrease in receptor density. We conclude that in the acute phase of 2K1C hypertension, antisense to AT_1A receptor decreases AT_1A receptor density, which attenuates the vascular vasoconstrictive effects of high plasma angiotensin II levels and in the kidney elicits natriuresis. The decrease in renal AT_1A receptor density may also lead to sodium loss and reduction of extracellular volume.

Key Words: hypertension, 2K1C • oligonucleotides, antisense AT₁-A receptors • angiotensin II

This article has been cited by other articles:

				D. M. Harris, H. I. Cohn, S. Pesant, R.-H. Zhou, and A. D. Eckhart Vascular smooth muscle Gq signaling is involved in high blood pressure in both induced renal and genetic vascular smooth muscle-derived models of hypertension Am J Physiol Heart Circ Physiol, November 1, 2007; 293(5): H3072 - H3079. [Abstract] [Full Text] [PDF]

				M. K. Raizada and S. D. Sarkissian Potential of Gene Therapy Strategy for the Treatment of Hypertension Hypertension, January 1, 2006; 47(1): 6 - 9. [Full Text] [PDF]

				H. Hiyoshi, K. Yayama, M. Takano, and H. Okamoto Angiotensin Type 2 Receptor-Mediated Phosphorylation of eNOS in the Aortas of Mice With 2-Kidney, 1-Clip Hypertension Hypertension, May 1, 2005; 45(5): 967 - 973. [Abstract] [Full Text] [PDF]

				J. Vazquez, M. F. C. de Adjounian, C. Sumners, A. Gonzalez, C. Diez-Freire, and M. K. Raizada Selective Silencing of Angiotensin Receptor Subtype 1a (AT1aR) by RNA Interference Hypertension, January 1, 2005; 45(1): 115 - 119. [Abstract] [Full Text] [PDF]

				E. Lazartigues, A. J. Lawrence, F. S. Lamb, and R. L. Davisson Renovascular Hypertension in Mice With Brain-Selective Overexpression of AT1a Receptors Is Buffered by Increased Nitric Oxide Production in the Periphery Circ. Res., September 3, 2004; 95(5): 523 - 531. [Abstract] [Full Text] [PDF]

				M. I. Phillips Gene Therapy for Hypertension: The Preclinical Data Hypertension, September 1, 2001; 38(3): 543 - 548. [Abstract] [Full Text] [PDF]